Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Colorectal Neoplasms

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 33 articles:
HTML format



Single Articles


    November 2023
  1. MORINAKA T, Sakai N, Takayashiki T, Kuboki S, et al
    RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity.
    Int J Oncol. 2023;63:120.
    PubMed     Abstract available


  2. PANTALONE MR, Martin Almazan N, Lattanzio R, Taher C, et al
    Human cytomegalovirus infection enhances 5?lipoxygenase and cycloxygenase?2 expression in colorectal cancer.
    Int J Oncol. 2023;63:116.
    PubMed     Abstract available


  3. SUN Q, Liu B, Lan Q, Su Z, et al
    Antimicrobial agent chloroxylenol targets beta?catenin?mediated Wnt signaling and exerts anticancer activity in colorectal cancer.
    Int J Oncol. 2023;63:121.
    PubMed     Abstract available


    August 2023
  4. PARK SY, Seo D, Jeon EH, Park JY, et al
    RPL27 contributes to colorectal cancer proliferation and stemness via PLK1 signaling.
    Int J Oncol. 2023;63:93.
    PubMed     Abstract available


  5. KOIZUMI K, Domoto T, Minamoto T, Satomura K, et al
    Deactivation of glycogen synthase kinase-3beta by heat shock‑inducible tumor small protein attenuates hyperthermia‑induced pro‑migratory activity in colorectal cancer cells.
    Int J Oncol. 2023;63:92.
    PubMed     Abstract available


    July 2023
  6. LIU W, Zhang Z, Luo X, Qian K, et al
    m(6)A‑mediated LINC02038 inhibits colorectal cancer progression via regulation of the FAM172A/PI3K/AKT pathway via competitive binding with miR‑552‑5p.
    Int J Oncol. 2023;63:81.
    PubMed     Abstract available


    May 2023
  7. CUI K, Wu H, Zhang L, Li H, et al
    A novel lncRNA 495810 promotes the aerobic glycolysis in colorectal cancer by stabilizing pyruvate kinase isozyme M2.
    Int J Oncol. 2023;62:58.
    PubMed     Abstract available


    April 2023
  8. OH HH, Park YL, Park SY, Joo YE, et al
    A disintegrin and metalloprotease 12 contributes to colorectal cancer metastasis by regulating epithelial‑mesenchymal transition.
    Int J Oncol. 2023;62:50.
    PubMed     Abstract available


    March 2023
  9. CHEN J, Xu J, Yang J, Zhan Y, et al
    alpha‑hederin overcomes hypoxia‑mediated drug resistance in colorectal cancer by inhibiting the AKT/Bcl2 pathway.
    Int J Oncol. 2023;62:33.
    PubMed     Abstract available


  10. LIU P, Liu J, Ding M, Liu Y, et al
    FUT2 promotes the tumorigenicity and metastasis of colorectal cancer cells via the Wnt/beta‑catenin pathway.
    Int J Oncol. 2023;62:35.
    PubMed     Abstract available


    February 2023
  11. CHEN Y, Chen M, Deng K
    Blocking the Wnt/beta‑catenin signaling pathway to treat colorectal cancer: Strategies to improve current therapies (Review).
    Int J Oncol. 2023;62:24.
    PubMed     Abstract available


    January 2023
  12. SUI L, Zeng J, Zhao H, Ye L, et al
    Death associated protein3 (DAP3) and DAP3 binding cell death enhancer1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance.
    Int J Oncol. 2023;62.
    PubMed     Abstract available


  13. LEE YJ, Jung E, Choi J, Hwang JS, et al
    The EDN1/EDNRA/beta‑arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation.
    Int J Oncol. 2023;62:13.
    PubMed     Abstract available


    December 2022
  14. RAO X, Lin L
    Circadian clock as a possible control point in colorectal cancer progression (Review).
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    November 2022
  15. PAUL S, Bhardwaj M, Kang SC
    GSTO1 confers drug resistance in HCT116 colon cancer cells through an interaction with TNFalphaIP3/A20.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    October 2022
  16. DENG Y, Fu H, Han X, Li Y, et al
    Activation of DDX58/RIGI suppresses the growth of tumor cells by inhibiting STAT3/CSE signaling in colon cancer.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    September 2022
  17. LI M, Xia M, Zhang Z, Tan Y, et al
    METTL3 antagonizes 5FU chemotherapy and confers drug resistance in colorectal carcinoma.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


  18. TERADO T, Kim CJ, Ushio A, Minami K, et al
    Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRASactivated pancreatic cancer cells.
    Int J Oncol. 2022;61.
    PubMed     Abstract available


    June 2022
  19. CHANG CC, Kao WY, Liu CY, Su HH, et al
    Butyrate supplementation regulates expression of chromosome segregation 1like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  20. CITRIN D, Valle L, Camphausen K, Cooley-Zgela T, et al
    Pilot trial of topical MTS01 application to reduce dermatitis in patients receiving chemoradiotherapy for stage IIII carcinoma of the anal canal.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  21. ZHAO Q, Long Y, Cheng W, Huang Y, et al
    Visfatin inhibits colon cancer cell apoptosis and decreases chemosensitivity to 5FU by promoting the SDF1/CXCR4/Akt axis.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  22. BRUNO G, Li Bergolis V, Piscazzi A, Crispo F, et al
    TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    March 2022
  23. ABDULLA M, Traiki TB, Vaali-Mohammed MA, El-Wetidy MS, et al
    Targeting MUCL1 protein inhibits cell proliferation and EMT by deregulating betacatenin and increases irinotecan sensitivity in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    February 2022
  24. WANG J, Yokoyama Y, Hirose H, Shimomura Y, et al
    Functional assessment of miR1291 in colon cancer cells.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  25. CHEN S, Nishi M, Morine Y, Shimada M, et al
    Epigallocatechin3gallate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancerassociated fibroblasts.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  26. BAHR I, Jaeschke L, Nimptsch K, Janke J, et al
    Obesity, colorectal cancer and MACC1 expression: A possible novel molecular association.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  27. PAN S, Deng Y, Fu J, Zhang Y, et al
    N6methyladenosine upregulates miR181d5p in exosomes derived from cancerassociated fibroblasts to inhibit 5FU sensitivity by targeting NCALD in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    January 2022
  28. LIAO Z, Zhang H, Fan P, Huang Q, et al
    [Corrigendum] High PLK4 expression promotes tumor progression and induces epithelialmesenchymal transition by regulating the Wnt/betacatenin signaling pathway in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


  29. WATANABE K, Shiga K, Maeda A, Harata S, et al
    Chitinase 3-like 1 secreted from cancer-associated fibroblasts promotes tumor angiogenesis via interleukin-8 secretion in colorectal cancer.
    Int J Oncol. 2022;60.
    PubMed     Abstract available


    December 2021
  30. SHI W, Men L, Pi X, Jiang T, et al
    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL6/STAT3 signaling pathway.
    Int J Oncol. 2021;59.
    PubMed     Abstract available


    March 2021
  31. HA THI HT, Duong HQ, Hong S
    Emerging roles of noncoding RNAs in the response of rectal cancer to radiotherapy (Review).
    Int J Oncol. 2021;58:344-358.
    PubMed     Abstract available


    February 2021
  32. ANDO S, Fukamachi K, Yoshimoto E, Matsumoto H, et al
    Palmitoyl piperidinopiperidine, a novel derivative of 10hydroxy2decenoic acid, as a potent and selective anticancer agent against human colon carcinoma cell lines.
    Int J Oncol. 2021;58:251-265.
    PubMed     Abstract available


    September 2020
  33. FENG J, Xiao T, Lu SS, Hung XP, et al
    ANXA1derived peptides suppress gastric and colon cancer cell growth by targeting EphA2 degradation.
    Int J Oncol. 2020 Sep 7. doi: 10.3892/ijo.2020.5119.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: